READ BOBBY AND TED'S STORY CLICK ON PHOTO
READ SQUEEZY'S STORY CLICK ON PHOTO

email forum - by joining the group e-mail forum you will be in contact with Alpha patients, their families, carers and friends living throughout the UK and overseas. We are a friendly group, and between us we have a wealth of knowledge and experience to share. There is always someone to help with any worries or queries you might have.

What is Alpha-1 Antitrypsin Deficiency?

Alpha-1 Antitrypsin Deficiency also known as Alpha-1, A1AD or AATD is an inherited, genetic condition that is passed on from generation to generation. As the name suggests it is a deficiency of alpha-1 antitrypsin (AAT) in the bloodstream. AAT is an enzyme produced in the liver to help protect the tissues of the body during infections. The low level of AAT in the blood occurs because the AAT is abnormal and cannot be released from the liver at the normal rate. This leads to a build up of abnormal AAT in the liver that can cause liver disease and a decrease of AAT in the blood that can lead to lung disease.

Newsletter Autumn 2018 Now Available


Autumn 2018 Alpha-1 UK Newsletter Issue 17
Now Available

Contains 36 pages full of News and Information including:

21 years Alpha-1 UK Support Coming of Age, Research & Global Congress update, Members Stories and much more

 

Top Story

UK sites now open for new drug trial (Astraeus Study) to explore oral compound for Alpha-1 lung disease

8 clinical trial sites now open across the UK for ASTRAEUS Study 

Alpha-1 UK Support Group and Alpha-1 Awareness are pleased to note that all eight of the planned clinical trial sites to test alvelestat in Alpha-1 lung disease (the Astraeus Study) across the UK are now open, following the addition of a site in Exeter. This ensures that Alphas in the South-West of England are also given access to the clinical trial via a regional centre.                  

The eight Astraeus sites are spread geographically across the UK, from Edinburgh in Scotland, to Coventry and Birmingham in the middle of the country, down to Southampton and Exeter.  For a list of participating sites, please see www.astraeus-alpha1.com/en-GB/public/Referral

If you are interested in participating in the trial, you are free to approach any site of your choice, no matter where you are usually treated for your Alpha-1.  You can do this 
via the Astraeus site.  Given the requirement to visit the centre regularly during the 12-week trial duration, you might want to consider a trial site that is close to you, or you might not mind travelling further – the choice is yours.

If you are told that your first-choice centre is full, please see if your second choice of site is accepting participants – again, this can be found on the Astraeus site. You can also contact us if you encounter any issues.

Lastly, please remember that a clinical trial is a lot of work for the physician concerned as well as a big commitment from the participating patients, so whichever centre you sign up for the trial at, you should be confident that you will be able to manage travel to that site for every study visit.  Dropping out of a trial before the anticipated trial duration weakens the result of a trial.

As mentioned in our previous post back in March, the Astraeus Study is testing the safety of a research drug and whether it has the potential to reduce lung damage and slow the progression of lung disease caused by Alpha-1 Antitrypsin Deficiency.  The potential treatment, alvelestat, is taken as tablets and has already been tested in people with other lung diseases.

You must meet the study inclusion criteria which, amongst others, include the age range of between 18 to 75 years and a diagnosis of Alpha-1 Antitrypsin Deficiency lung disease with either PiZZ or Null genotype.  The referral section of the Astraeus website will help you make the initial determination and also direct you towards the different physicians leading the trial centres.  The physicians at the different trial centres will be able to advise if you are eligible based on the study criteria, which have been agreed by the regulatory ethics committees here in the UK.

All details are available on the UK website www.astraeus-alpha1.com, where you will be able to find more details, check if you are eligible for the study and get in contact with a trial centre near to you.  There are also details on the official clinical trial registry:  www.clinicaltrials.gov/ct2/show/NCT03636347.

Enrolled participants will receive all study-related care, testing and study medication at no cost.  You will receive study drug for about 12 weeks and you will be in the study for approximately 20 weeks in total.  You will need to visit the research site about nine times and receive two phone calls during the study.

For more information, please see:  www.astraeus-alpha1.com.

Please remember that patient participation in clinical research studies is critical for the development of new treatments for Alpha-1 – we need you!

Translate

Bookmark This
Follow Us

Latest News

Mereo Alvelestat Study Update
14 Jun 2019 12:00


UK sites now open for new drug trial (Astraeus Study) to explore oral compound for Alpha-1 lung disease   8 clinical trial sites now open across  [ ... ]

Read More
Sandra Takeda Keynote
11 Jun 2019 12:00


Alpha-1 UK Support Group would like to congratulate our Trustee, Sandra Nestler-Parr, who today has delivered the keynote opening presentation at Ta [ ... ]

Read More
Mereo Alvelestat Study
08 Mar 2019 12:00


Alpha-1 UK Support Group & Alpha-1 Awareness are very pleased to announce exciting news about a new drug trial for the UK   UK trial sites op [ ... ]

Read More
Keith Pollard
05 Dec 2018 19:30Keith Pollard


Keith Pollard is kindly donating the net proceeds of his book to the Alpha-1 UK Support in memory of his son Jason    

This remarkable new  [ ... ]

Read More

Thank You!

 
 

 
 

 
 
       

Fundraising